Literature DB >> 3472899

The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester.

L Z Bito, R A Baroody.   

Abstract

These experiments were undertaken to determine whether the increased ocular hypotensive potency of topically applied prostaglandin (PG) PGF2 alpha esters, as compared with that of PGF2 alpha free acid, can be accounted for by increased penetration of the eicosanoid moiety of the esterified PG into the eye. One hour after the topical application of [3H]PGF2 alpha-1-methyl ester (ME) in peanut oil, the 3H activities in the cornea, aqueous humor, and ciliary body of the rabbit eye were 32-, 22-, and 8-fold higher, respectively, than they were following the topical application of [3H]PGF2 alpha free acid. 3H activity during the first 3 hr declined rapidly in the cornea and more slowly in the aqueous humor, but remained essentially constant in the ciliary body for up to 6 hr, declining rapidly only between 6- and 24 hr. 3H activity in eyes that received [3H]PGF2 alpha ME was also several-fold higher in the anterior sclera and iris than in eyes that were treated with [3H]PGF2 alpha free acid, but this difference was much smaller in the conjunctiva. At 1 hr, most of the 3H activity in the aqueous humor was associated with PGF2 alpha, as determined by chromatography, but at 2- and 3 hr other peaks, presumably reflecting metabolites of PGF2 alpha, became apparent. The penetration and intraocular distribution of 3H activity was similar when [3H]PGF2 alpha ME was applied to the eye in normal saline rather than in peanut oil or when the isopropyl rather than the methyl ester of PGF2 alpha was used. These studies indicate that esterification of the carboxyl group of PGF2 alpha greatly enhances the penetration of the PGF2 alpha moiety into the eye and suggests that effective de-esterification of the PGF2 alpha ester occurs in the cornea, resulting in the delivery of PGF2 alpha free acid into the aqueous humor. It is concluded that topically applied PG esters act as pro-drugs and that the increased ocular penetration of these esters may account for the previously reported increase in their ocular hypotensive potency as compared to that of PG free acid or salts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472899     DOI: 10.1016/s0014-4835(87)80006-4

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

Review 1.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

2.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

Review 3.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  A Second Generation Prostanoid Receptor Antagonist Acting at Multiple Receptor Subtypes.

Authors:  David F Woodward; Jenny W Wang; Clayton S Spada; Robert W Carling; Jose L Martos; Simon Pettit; Jussi Kangasmetsa; L David Waterbury; Matthew Lawrence; Wenzheng Hu; Neil J Poloso
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-26

Review 5.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

6.  Studies on a novel series of acyl ester prodrugs of prostaglandin F2 alpha.

Authors:  A Cheng-Bennett; M F Chan; G Chen; T Gac; M E Garst; C Gluchowski; L J Kaplan; C E Protzman; M B Roof; G Sachs
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 7.  Latanoprost in the treatment of glaucoma.

Authors:  Albert Alm
Journal:  Clin Ophthalmol       Date:  2014-09-26

Review 8.  Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Authors:  Luciano Quaranta; Ivano Riva; Andreas Katsanos; Irene Floriani; Marco Centofanti; Anastasios G P Konstas
Journal:  Clin Ophthalmol       Date:  2015-04-10

9.  The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors.

Authors:  R A Coleman; A J Woodrooffe; K L Clark; C B Toris; S Fan; J W Wang; D F Woodward
Journal:  Br J Pharmacol       Date:  2019-01-04       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.